Does Dr. IFRAH ABDIRAHMAN have financial conflicts of interest?

Dr. IFRAH ABDIRAHMAN (MD) has received a total of $315 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $315 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. IFRAH ABDIRAHMAN?

According to CMS Open Payments data, Dr. IFRAH ABDIRAHMAN received funding from ASTRAZENECA PHARMACEUTICALS ($217), UNITED THERAPEUTICS CORPORATION ($84), and PFIZER ($14).

Does Dr. IFRAH ABDIRAHMAN receive research grants or speaking fees?

Dr. IFRAH ABDIRAHMAN has received $315 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. IFRAH ABDIRAHMAN

MDReal-Time Hydrated

Specialty: Internal Medicine, Advanced Heart Failure and Transplant Cardiology

Practice Location: NORWICH, NY 13815

NPI Number: 1790373926

LIFETIME INDUSTRY VALUE

$315

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDIRAHMAN is a verified Internal Medicine, Advanced Heart Failure and Transplant Cardiology practitioner based in NORWICH, NY.

Between 2021 and 2024, Dr. ABDIRAHMAN had an overall industry promotional and research financial footprint of $315 as recorded in the federal CMS Open Payments database.

$315 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDIRAHMAN's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $217 (representing 69% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$217

69%

UNITED THERAPEUTICS CORPORATION

Rank 2

$84

26.6%

PFIZER

Rank 3

$14

4.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.